



**2014 Spring Meeting of Participants
SPECIAL PLENARY SESSION AND AWARDS CEREMONY**

Friday, May 2, 2014

4:30 – 6:00 pm

Special Plenary Session – Dr. Penny Bradbury, Chair

Topic	Presenter
BR.26: A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease	Dr. Peter Ellis
Estimation of Cost Avoidance in NCIC CTG Phase III Clinical Trials	Dr. Patricia Tang
IND.206: A Phase II Study of Sunitinib or Temozolomide in Patients with Advanced Rare Tumours	Dr. Hal Hirte
LY.12: Randomized Phase III Study of Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas – Part 2	Dr. Michael Crump

NCIC CTG Awards Ceremony – Dr. Elizabeth Eisenhauer, Chair

- **Joseph Pater Founder’s Award for Excellence in Clinical Trials Research**
 - 2014 Recipient – Dr. Vivien Bramwell
- **Ralph Meyer Phase III Young Investigator Award**
 - 2014 Recipient – Dr. Annette Hay
- **Elizabeth Eisenhauer Early Drug Development Young Investigator Award**
 - 2014 Recipient – Dr. Daniel Renouf
- **Early Drug Development Team Award**
 - 2014 Recipients:
 - IND.211 – CHUM Hôpital Notre-Dame
 - IND.210 – Ottawa Hospital Research Institute
- **Phase III Program Team Award**
 - 2014 Recipients:
 - MA.32 – Vancouver Centre - BC Cancer Agency
 - BR.26 – Princess Margaret Cancer Centre